| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Huzhangoside D does not have a well-defined specific therapeutic target but is a naturally occurring triterpenoid saponin. As a saponin, it may interact with cell membranes and exhibit various biological activities. Saponins are known for their diverse pharmacological properties, including anti-inflammatory, immunomodulatory, and anticancer effects. The compound's mechanism of action may involve modulation of immune responses or interaction with membrane components.
|
|---|---|
| ln Vitro |
Huzhangoside D is a triterpenoid saponin compound with potential biological activities. As a natural product, it is part of a class of compounds known for diverse biological activities including anti-inflammatory, immunomodulatory, and anticancer effects. The compound's specific biological activities and potency values are not extensively documented in the public domain. It is used in natural product research.
|
| ln Vivo |
In vivo activity data for Huzhangoside D are not extensively documented. As a natural product, it may have potential for various biological activities, but specific in vivo efficacy studies in animal models are not specified in the public domain. The compound is intended for research use only and is not approved for human therapeutic applications. Further studies are needed to evaluate its in vivo pharmacokinetics and pharmacodynamics.
|
| Enzyme Assay |
The in vitro assay for Huzhangoside D typically involves its use as a reference standard in natural product research. The compound is analyzed by HPLC to confirm purity. For biological activity assessment, cells are treated with varying concentrations of the compound (typically 0.1-100 µM) for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or CellTiter-Glo assays. The compound is dissolved in DMSO and diluted in cell culture medium.
|
| Cell Assay |
In vitro cellular assays for Huzhangoside D typically involve treating various cell lines with the compound at concentrations ranging from 0.1 to 100 µM for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or CellTiter-Glo assays. The compound's effects on cell proliferation, apoptosis, and signaling pathways are evaluated using standard methods. The compound is dissolved in DMSO as a stock solution and diluted in cell culture medium.
|
| Animal Protocol |
In vivo animal studies for Huzhangoside D are not extensively documented. For potential in vivo applications, the compound could be administered to mice via oral gavage or intraperitoneal injection at doses determined from preliminary studies. The compound's pharmacokinetics and pharmacodynamics would be evaluated in these models. Standard efficacy studies would involve appropriate disease models depending on the compound's suspected biological activity.
|
| ADME/Pharmacokinetics |
Huzhangoside D has a molecular weight of 1000+ g/mol (typical for triterpenoid saponins). It is a triterpenoid saponin compound. The compound is soluble in organic solvents such as DMSO and methanol. Recommended storage is typically -20°C for powder. Detailed PK parameters such as half-life, Cmax, AUC, and bioavailability would require experimental determination.
|
| Toxicity/Toxicokinetics |
Huzhangoside D is intended for research use only and is not approved for human therapeutic applications. As a natural product, it may have a favorable safety profile, but appropriate safety precautions should be taken when handling. Standard toxicity assessments would include acute toxicity, genotoxicity, and repeated-dose toxicity studies if required for specific applications.
|
| References | |
| Additional Infomation |
According to reports, citronellol D has been found in Hubei anemone, Tibetan clematis, and other organisms with available data.
Huzhangoside D (CAS 96315-53-6) is a triterpenoid saponin compound used in natural product research. Saponins are known for their diverse biological activities including anti-inflammatory, immunomodulatory, and anticancer effects. Huzhangoside D is not approved for clinical use and is intended for research purposes only. |
| Molecular Formula |
C64H104O30
|
|---|---|
| Molecular Weight |
1352
|
| Exact Mass |
1352.661
|
| CAS # |
96315-53-6
|
| PubChem CID |
49799270
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.645
|
| LogP |
4.51
|
| Hydrogen Bond Donor Count |
17
|
| Hydrogen Bond Acceptor Count |
30
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
94
|
| Complexity |
2640
|
| Defined Atom Stereocenter Count |
37
|
| SMILES |
C([C@]12CCC(C)(C)C[C@H]1C1=CC[C@@H]3[C@]4(CC[C@H](O[C@@H]5OC[C@H](O)[C@H](O)[C@H]5O[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O[C@@H]6OC[C@@H](O)[C@@H](O)[C@H]6O)[C@H]5O)[C@@](C)(CO)[C@@H]4CC[C@@]3(C)[C@@]1(CC2)C)C)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](CO)O2)O1
|
| InChi Key |
PLQZZVHULIUSEV-FXDKWXKUSA-N
|
| InChi Code |
InChI=1S/C64H104O30/c1-25-36(69)41(74)45(78)54(86-25)91-49-31(20-65)88-52(47(80)43(49)76)85-23-32-40(73)42(75)46(79)55(89-32)94-58(82)64-17-15-59(3,4)19-28(64)27-9-10-34-60(5)13-12-35(61(6,24-66)33(60)11-14-63(34,8)62(27,7)16-18-64)90-57-51(39(72)30(68)22-84-57)93-56-48(81)50(37(70)26(2)87-56)92-53-44(77)38(71)29(67)21-83-53/h9,25-26,28-57,65-81H,10-24H2,1-8H3/t25-,26-,28-,29+,30-,31+,32+,33+,34+,35-,36-,37-,38+,39-,40+,41+,42-,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53-,54-,55-,56-,57-,60-,61-,62+,63+,64-/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-3-[(2S,3R,4R,5S,6S)-3,5-dihydroxy-6-methyl-4-[(2S,3R,4R,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7396 mL | 3.6982 mL | 7.3964 mL | |
| 5 mM | 0.1479 mL | 0.7396 mL | 1.4793 mL | |
| 10 mM | 0.0740 mL | 0.3698 mL | 0.7396 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
